Trial Outcomes & Findings for Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region (NCT NCT00422227)
NCT ID: NCT00422227
Last Updated: 2010-08-30
Results Overview
ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.
COMPLETED
PHASE4
300 participants
16 weeks
2010-08-30
Participant Flow
Subjects were recruited in the Asia-Pacific Region from June 2007 to October 2008.
Screening of subjects occurred up to 2 weeks before randomization followed by a treatment phase of 16 weeks and a 2-week safety follow up.
Participant milestones
| Measure |
ETN/MTX
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Overall Study
STARTED
|
197
|
103
|
|
Overall Study
COMPLETED
|
193
|
88
|
|
Overall Study
NOT COMPLETED
|
4
|
15
|
Reasons for withdrawal
| Measure |
ETN/MTX
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Overall Study
Adverse Event
|
3
|
8
|
|
Overall Study
Lost to Follow-up
|
1
|
3
|
|
Overall Study
Withdrawal by Subject
|
0
|
4
|
Baseline Characteristics
Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region
Baseline characteristics by cohort
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
Total
n=300 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age Continuous
|
48.38 years
STANDARD_DEVIATION 11.98 • n=39 Participants
|
48.52 years
STANDARD_DEVIATION 11.25 • n=41 Participants
|
48.43 years
STANDARD_DEVIATION 11.72 • n=35 Participants
|
|
Sex: Female, Male
Female
|
180 Participants
n=39 Participants
|
91 Participants
n=41 Participants
|
271 Participants
n=35 Participants
|
|
Sex: Female, Male
Male
|
17 Participants
n=39 Participants
|
12 Participants
n=41 Participants
|
29 Participants
n=35 Participants
|
PRIMARY outcome
Timeframe: 16 weeksPopulation: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.
Outcome measures
| Measure |
ETN/MTX
n=194 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=98 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks
|
434.83 Units on a scale
Standard Error 29.18
|
289.54 Units on a scale
Standard Error 36.11
|
SECONDARY outcome
Timeframe: Week 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability.
Outcome measures
| Measure |
ETN/MTX
n=194 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=98 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
ACR 20
|
78.87 Percentage of Participants
|
58.16 Percentage of Participants
|
|
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
ACR 50
|
56.70 Percentage of Participants
|
34.69 Percentage of Participants
|
|
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
ACR 70
|
19.07 Percentage of Participants
|
7.14 Percentage of Participants
|
SECONDARY outcome
Timeframe: Week 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
Low Disease (DAS28 <3.2)
|
39.09 Percentage of Participants
|
18.45 Percentage of Participants
|
|
Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
Remission (DAS28 <2.6)
|
15.74 Percentage of Participants
|
7.77 Percentage of Participants
|
SECONDARY outcome
Timeframe: Week 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percent Change From Baseline in DAS28 at Week 16
|
38.32 Percent change
|
27.46 Percent change
|
SECONDARY outcome
Timeframe: Week 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as \>1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of \>0.6 but ≤1.2 and DAS attained during follow-up of \>3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response.
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response
|
87.82 Percentage of Participants
|
73.79 Percentage of Participants
|
SECONDARY outcome
Timeframe: Week 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
≥0.6
|
91.37 Percentage of Participants
|
78.64 Percentage of Participants
|
|
Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
≥1.2
|
82.74 Percentage of Participants
|
66.02 Percentage of Participants
|
SECONDARY outcome
Timeframe: Week 2, 4, 8, 12, 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen.
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 2
|
34.17 Percent change
|
27.68 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 4
|
46.11 Percent change
|
36.71 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 8
|
55.48 Percent change
|
49.71 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 12
|
65.65 Percent change
|
55.55 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 16
|
68.99 Percent change
|
57.31 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 2
|
38.59 Percent change
|
21.32 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 4
|
49.33 Percent change
|
27.72 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 8
|
59.91 Percent change
|
44.19 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 12
|
67.97 Percent change
|
50.48 Percent change
|
|
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 16
|
73.83 Percent change
|
56.32 Percent change
|
SECONDARY outcome
Timeframe: Week 2, 4, 8, 12, 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity.
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 2
|
30.40 Percent change
|
11.83 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 4
|
39.58 Percent change
|
22.81 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 8
|
45.86 Percent change
|
35.41 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 12
|
55.00 Percent change
|
38.67 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 16
|
62.05 Percent change
|
45.04 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 2
|
21.84 Percent change
|
7.24 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 4
|
28.94 Percent change
|
19.22 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 8
|
34.92 Percent change
|
26.08 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 12
|
43.18 Percent change
|
30.10 Percent change
|
|
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 16
|
50.76 Percent change
|
30.55 Percent change
|
SECONDARY outcome
Timeframe: Week 2, 4, 8, 12, 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded.
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 2
|
54.92 Percent change
|
16.43 Percent change
|
|
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 4
|
63.85 Percent change
|
33.22 Percent change
|
|
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 8
|
73.41 Percent change
|
37.35 Percent change
|
|
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 12
|
79.76 Percent change
|
52.76 Percent change
|
|
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 16
|
80.55 Percent change
|
46.77 Percent change
|
SECONDARY outcome
Timeframe: Week 2, 4, 8, 12, 16Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.
VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, "in general how would you rate your heath over the last 2-3 weeks", 0mm equals very well and 100mm equals extremely bad. Pain VAS: "indicate the amount of pain experienced during the last 2-3 days", 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: "how fatigued or tired have you been over the last week", range =No Fatigue - Extremely Fatigued.
Outcome measures
| Measure |
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 2
|
21.14 Percent change
|
8.88 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 4
|
30.61 Percent change
|
22.78 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 8
|
38.57 Percent change
|
27.86 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 12
|
42.10 Percent change
|
30.26 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 16
|
50.49 Percent change
|
33.89 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 2
|
27.59 Percent change
|
9.99 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 4
|
34.73 Percent change
|
22.98 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 8
|
42.97 Percent change
|
29.14 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 12
|
48.46 Percent change
|
33.97 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 16
|
54.42 Percent change
|
36.45 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 2
|
20.90 Percent change
|
6.63 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 4
|
30.87 Percent change
|
19.00 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 8
|
35.92 Percent change
|
21.82 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 12
|
39.65 Percent change
|
28.65 Percent change
|
|
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 16
|
46.92 Percent change
|
30.04 Percent change
|
Adverse Events
ETN/MTX
DMARD/MTX
Serious adverse events
| Measure |
ETN/MTX
n=197 participants at risk
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 participants at risk
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Cardiac disorders
Myocardial infarction
|
0.51%
1/197
|
0.00%
0/103
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.51%
1/197
|
0.00%
0/103
|
|
General disorders
Non-cardiac chest pain
|
0.51%
1/197
|
0.00%
0/103
|
|
Infections and infestations
Cellulitis
|
0.51%
1/197
|
0.00%
0/103
|
|
Infections and infestations
Herpes zoster
|
0.51%
1/197
|
0.00%
0/103
|
|
Infections and infestations
Pneumocystis jiroveci pneumonia
|
0.51%
1/197
|
0.00%
0/103
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/197
|
0.97%
1/103
|
|
Injury, poisoning and procedural complications
Fall
|
0.51%
1/197
|
0.00%
0/103
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.51%
1/197
|
0.00%
0/103
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.51%
1/197
|
0.00%
0/103
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.51%
1/197
|
0.00%
0/103
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/197
|
0.97%
1/103
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/197
|
0.97%
1/103
|
|
Investigations
Transaminases increased
|
0.00%
0/197
|
0.97%
1/103
|
Other adverse events
| Measure |
ETN/MTX
n=197 participants at risk
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
|
DMARD/MTX
n=103 participants at risk
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
|
|---|---|---|
|
Blood and lymphatic system disorders
Leukopenia
|
2.0%
4/197
|
7.8%
8/103
|
|
Gastrointestinal disorders
Nausea
|
2.0%
4/197
|
7.8%
8/103
|
|
General disorders
Pyrexia
|
3.0%
6/197
|
5.8%
6/103
|
|
Infections and infestations
Upper respiratory tract infection
|
13.7%
27/197
|
15.5%
16/103
|
|
Investigations
Alanine aminotransferase increased
|
5.6%
11/197
|
14.6%
15/103
|
|
Investigations
Aspartate aminotransferase increased
|
3.6%
7/197
|
10.7%
11/103
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
3.6%
7/197
|
6.8%
7/103
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.
- Publication restrictions are in place
Restriction type: OTHER